Therefore, given the analysis of the power to detect GEN1 variants in our discovery sequencing phase by binominal distribution (among 617 Polish HBC families), a large-scale multicenter association study in our genotyping validation phase, which included approximately 16,000 unselected breast cancer cases and 5000 controls from all over Poland, and a genetic homogeneity of the Polish population, we consider that we have sufficient data and power to detect possible associations between GEN1 and breast cancer susceptibility. The gene discussed is GEN1; the disease is breast cancer.